UBS/CALL/ROCHE GS/360.004/0.025/18.12.26 Share Price

Warrant

QROGQU

CH1278650424

Real-time Bid/Ask 07:43:06 03/06/2024 pm IST
0.071 CHF / 0.08 CHF -1.30% Intraday chart for UBS/CALL/ROCHE GS/360.004/0.025/18.12.26
3 months+2.67%
6 months+5.48%
Date Price Change
31/24/31 0.077 -3.75%

Delayed Quote Swiss Exchange

Last update May 31, 2024 at 08:50 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
QROGQU
ISINCH1278650424
Date issued 26/06/2023
Strike 360 CHF
Maturity 18/12/2026 (928 Days)
Parity 40 : 1
Emission price 0.23 CHF
Emission volume N/A
Settlement Por entregas
Currency CHF

Technical Indicators

Highest since issue 0.22 CHF
Lowest since issue 0.066 CHF
Delta0.09x
Omega 7.133
Premium56.72x
Gearing78.24x
Moneyness 0.6433
Difference Strike 128.4 CHF
Difference Strike %+35.67%
Spread 0.01 CHF
Spread %12.66%
Theoretical value 0.0740
Implied Volatility 21.00 %
Total Loss Probability 95.14 %
Intrinsic value 0.000000
Present value 0.0740
Break even 362.96 CHF
Theta-0x
Vega0.01x
Rho0.01x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Warrants
  3. QROGQU Warrant